Mesenchymal Stem Cell Isolation Using IGF1R and Human Cord Blood Serum
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and cultivating mesenchymal stem cells with multipotent differentiation capabilities are inefficient and may involve risks such as allergic reactions and viral infections from non-human sera, and there is a need for effective treatments for ischemic heart disease and brain tissue damage.
Innovation Solution
Isolation and cultivation of mesenchymal stem cells expressing insulin-like growth factor 1 receptor (IGF1R) using human cord blood serum, which enhances receptor expression and multipotent differentiation, and subsequent use in treating ischemic heart disease and brain tissue damage by attenuating post-myocardial infarction effects and promoting angiogenesis and neurite regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If non-human sera are used for cultivating mesenchymal stem cells, then cell proliferation is supported, but allergic reactions and viral infections occur
Solution Approach 1:
The patent replaces expensive and hazardous non-human sera with human cord blood serum, which is safer and equally effective for supporting mesenchymal stem cell proliferation while eliminating the risks of allergic reactions and viral infections associated with animal-derived sera
Solution Approach 2:
The patent changes the source parameter of the serum from non-human (animal) to human origin, specifically using human cord blood serum, which maintains the nutritional and growth factors needed for cell proliferation while removing the harmful immunogenic components present in animal sera
2Productivity
If conventional methods are used to isolate mesenchymal stem cells, then cells can be obtained, but isolation efficiency is low and multipotent differentiation capability is compromised
Solution Approach 1:
The patent applies local quality by selecting and enriching for a specific subpopulation of mesenchymal stem cells that exhibit high expression of the insulin-like growth factor 1 receptor (IGF1R), thereby obtaining a cell population with enhanced and more reliable multipotent differentiation capability compared to conventional bulk isolation methods
Solution Approach 2:
The patent uses IGF1R expression level as a selection parameter to isolate mesenchymal stem cells, changing from conventional markers to this specific receptor expression criterion, which results in both higher isolation efficiency of functional cells and preserved multipotent differentiation capability
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Provided are a mesenchymal stem cell, a clonogenic amplification method thereof, a separation method thereof and uses thereof. The mesenchymal stem cell expresses an insulin-like growth factor-1 receptor, and has a self-renewal capability and the capability for pluripotent differentiation.